Literature DB >> 21997945

Post-operative ocular infection due to Streptococcus dysgalactiae subspecies equisimilis.

Jayaraman Kaliamurthy1, Vincenzo Cuteri, Nelson Jesudasen, Amjad Salman, Philip A Thomas, Silvia Preziuso.   

Abstract

Ocular infections due to Streptococcus dysgalactiae subsp. equisimilis are rare. In the present report, three patients with a history of uncomplicated small incision cataract surgery with intraocular lens implantation developed exogenous endophthalmitis due to Streptococcus dysgalactiae subsp. equisimilis. The identification of the organisms was confirmed by PCR for a 16S rRNA sequence specific to the species S. dysgalactiae. Intravitreal treatment of cefazolin and amikacin, in addition to topical ofloxacin and tobramycin, resulted in resolution of infection in all three patients. Our reports indicate the importance of bacterial culture and molecular identification in the diagnosis of S. dysgalactiae subsp. equisimilis infection in the eye.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997945     DOI: 10.3855/jidc.1758

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  3 in total

1.  A case report of fulminant endophthalmitis caused by Streptococcus dysgalactiae in a patient with traumatic corneal laceration.

Authors:  Yong Woo Lee; Kyung Min Koh; Kyu Yeon Hwang; Young A Kwon; Dong Won Lee; Sang Wroul Song; Byoung Yeop Kim; Kook Young Kim
Journal:  BMC Ophthalmol       Date:  2020-06-18       Impact factor: 2.209

Review 2.  The pathogenicity of the Streptococcus genus.

Authors:  W Krzyściak; K K Pluskwa; A Jurczak; D Kościelniak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-03       Impact factor: 3.267

3.  Rapidly progressive streptococcus dysgalactiae corneal ulceration associated with erlotinib use in stage IV lung cancer.

Authors:  Ethan K Sobol; Sumayya Ahmad; Kirolos Ibrahim; Cesar Alfaro; Joel Pakett; Karina Esquenazi; David Della Rocca; Robin Ginsburg
Journal:  Am J Ophthalmol Case Rep       Date:  2020-02-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.